East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, “Cambrex”) will be exhibiting at the 3rd Annual World ADC Summit 2012, October 23-25 in San Francisco, CA.
Attendees are invited to visit Cambrex’s exhibit and learn more about the Company’s small molecule High Potency API (HPAPI) products and services designed to accelerate the commercialization of finished HPAPI drug products.
Cambrex will be showcasing its high potency contract service capabilities ranging from development services to cGMP manufacturing. Our portfolio of offerings includes cytotoxics, cytostatics controlled substances, ultra-potent cytotoxic drugs and linkers, as well as other high potency APIs.
For over 14 years, Cambrex has been developing and manufacturing a broad spectrum of HPAPIs. Cambrex routinely cGMP manufactures HPAPIs (up to 2000 L) and has the ability to scale-up toxicology to commercial quantities in a cGMP environment.